The PATHFINDER Study: A Feasibility Trial

Summary

The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.

Conditions

• Coronary Artery Disease
• Delirium

Interventions

DRUG

Ropivacaine

Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision

DRUG

Ketamine

Intraoperative infusion

DRUG

Remifentanil

Intraoperative infusion

DRUG

Dexmedetomidine

Intraoperative infusion

DRUG

Rocuronium

Intraoperative intermittent bolus

DRUG

Propofol

Intraoperative infusion

DRUG

Sevoflurane

Intraoperative inhaled as needed

DRUG

Dexmedetomidine

Post-operative infusion

DRUG

Propofol

Post-operative infusion

DEVICE

EEG monitoring

Perioperative monitoring

Sponsors & Collaborators

• Beth Israel Deaconess Medical Center

  lead OTHER

Principal Investigators

• Balachundhar Subramaniam, MD, MPH · Beth Israel Deaconess Medical Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-08-20

Primary Completion

2020-02-19

Completion

2020-07-07

FDA Drug

Yes

Countries

• United States

Study Locations